These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 21387248

  • 1. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.
    Horga A, Castillo J, Rio J, Tintore M, Auger C, Sastre-Garriga J, Edo MC, Perez-Miralles F, Tur C, Nos C, Huerga E, Comabella M, Rovira A, Montalban X.
    Rev Neurol; 2011 Mar 16; 52(6):321-30. PubMed ID: 21387248
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G.
    J Neurol Sci; 2011 Sep 15; 308(1-2):98-102. PubMed ID: 21665227
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2011 Sep 15; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    J Neurol Sci; 2010 May 15; 292(1-2):28-35. PubMed ID: 20236661
    [Abstract] [Full Text] [Related]

  • 9. Natalizumab dosage suspension: are we helping or hurting?
    West TW, Cree BA.
    Ann Neurol; 2010 Sep 15; 68(3):395-9. PubMed ID: 20818793
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab treatment in pediatric multiple sclerosis: a case report.
    Borriello G, Prosperini L, Luchetti A, Pozzilli C.
    Eur J Paediatr Neurol; 2009 Jan 15; 13(1):67-71. PubMed ID: 18406645
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
    Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B.
    Eur Neurol; 2010 Jan 15; 63(2):101-6. PubMed ID: 20090344
    [Abstract] [Full Text] [Related]

  • 13. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.
    JAMA Neurol; 2013 Apr 15; 70(4):469-75. PubMed ID: 23420110
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab use in pediatric multiple sclerosis.
    Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J.
    Arch Neurol; 2008 Dec 15; 65(12):1655-8. PubMed ID: 19064754
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Ann Neurol; 2007 Oct 15; 62(4):335-46. PubMed ID: 17696126
    [Abstract] [Full Text] [Related]

  • 17. Immunological markers of optimal response to natalizumab in multiple sclerosis.
    Villar LM, García-Sánchez MI, Costa-Frossard L, Espiño M, Roldán E, Páramo D, Lucas M, Izquierdo G, Álvarez-Cermeño JC.
    Arch Neurol; 2012 Feb 15; 69(2):191-7. PubMed ID: 22332187
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Feb 15; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 19. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 20. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar 04; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.